Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty-seven of them were common-ALL positive for CD10 "common-ALL antigen (CALLA)" (NL-1), CD19(B4) and HLA-DR. One was pre-B ALL negative for CALLA and another null-ALL which expressed HLA-DR alone.
|
2959808 |
1987 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This in vivo cell line, designated PALL-I, retained the Ph1 chromosome, t(9;22) (q34;q11), and pre-B-cell phenotype (SmIg-, CpIg-, CD10+, CD19+, OKIaI+, and CD38+), like the original leukemia cells.
|
2732004 |
1989 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency of CD45 expression did not differ between cases of early pre-B (CD19+, cytoplasmic mu-) and pre-B (CD19+, cytoplasmic mu+) ALL.
|
1531305 |
1992 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of these, 42 children with a common/pre-B phenotype (CD19/CD10-positive) were studied specifically to assess CD10 antigen density.
|
1465029 |
1992 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used this SCID mouse model of human pre-B ALL to evaluate and compare, in a total of 434 SCID mice, the antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin and cyclophosphamide (CPA) as individual reagents and as combined immunochemotherapeutic regimens.
|
1375841 |
1992 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used this SCID mouse model of aggressive human pre-B ALL to evaluate the in vivo antileukemic efficacy of B43 (anti-CD19)-pokeweed antiviral protein (PAP) immunotoxin.
|
1373967 |
1992 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The patterns observed here and those reported previously follow that of the pre B-ALL which confirms the engagement of most CD2 + CD19 + biphenotypic ALL in the B-lineage.
|
7686033 |
1993 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunophenotyping of the leukemic blasts led to the diagnosis common ALL (CD19+, CD10+, clg-).
|
8412330 |
1993 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, only two patients from a group of 67 common (CD19/CD10+, cylgM/sIgM-) and pre-B ALLs (CD19/cylgM+, CD10 +/-, sIgM-) showed ALL1-AF4 mRNA.
|
7949140 |
1994 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Likewise, cross-linking of CD19 with a monoclonal antibody in BCR-negative pro-B (RS4;11, 380) and pre-B (NALM6) cells induced Tec tyrosine phosphorylation and increased Tec autophosphorylation, as well as Btk activation.
|
9446655 |
1998 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the clinical features of this patient with the MLL-AF5q31 fusion transcript, characterized by the early pre-B phenotype (CD10(-)/CD19(+)) and poor outcome, were similar to those of patients having MLL-AF4 chimeric transcripts.
|
10588740 |
1999 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
None of the CD34(+)Lin(-) hematopoietic stem cell progenitors or the CD34(+)CD19(+) (pro-B) or the CD19(+)CD10(+) (pre-B/immature B cells) B-cell progenitors expressed CCR6.
|
11001880 |
2000 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The two remaining cases typed as early pre-B ALL (CD19+, CD10+), with one case co-expressing CD7.
|
11279625 |
2001 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to pro-B leukemia cells, pre-pre-B leukemia cells from children with CD19(+)CD10(+) common B-lineage ALL and EBV-transformed B-cell lines from healthy volunteers expressed wild-type Syk coding sequences.
|
11494125 |
2001 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To elucidate the biologic and clinical heterogeneity of adult pro-B acute lymphoblastic leukemia (ALL) (ie, terminal deoxynucletidyl-transferase-positive[TdT+], CD19+, CD10-, surface immunoglobulin-negative [SIg-]), we evaluated 66 patients enrolled in the Italian multicentric Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) 0496 study between October 1996 and December 1999.
|
12791662 |
2003 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19 negative precursor B acute lymphoblastic leukemia presenting with hypercalcemia.
|
15170892 |
2004 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro, bone marrow cells from young mice formed unique mixed pro-B lymphoid (B220(+)CD19(+)CD43(+)sIgM(-), PAX5(+), TdT(+), IgH rearranged)/myeloid (CD11b/Mac1(+), c-fms(+), lysozyme(+)) colonies when grown in IL-7- and Flt3 ligand-containing media.
|
16551973 |
2006 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A dual inhibitor of PI3K and mTOR, PI-103, was more effective than rapamycin at suppressing proliferation of mouse pre-B-ALL and human CD19+CD34+)Ph+ ALL leukemia cells treated with the ABL kinase inhibitor imatinib.
|
18704194 |
2008 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD19 is a pan B-cell surface receptor expressed from pro-B-cell development until its down-regulation during terminal differentiation into plasma cells.
|
18829563 |
2008 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ordering human CD34+CD10-CD19+ pre/pro-B-cell and CD19- common lymphoid progenitor stages in two pro-B-cell development pathways.
|
20231472 |
2010 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PB-derived CAR(+) CTLs produced interferon-gamma (IFNgamma) in response to cytomegalovirus-pp65, adenovirus-hexon, and Epstein-Barr virus pepmixes (from 205 +/- 104 to 1034 +/- 304 spot-forming cells [SFCs]/10(5) T cells) and lysed primary B-ALL blasts in (51)Cr-release assays (mean, 66% +/- 5% specific lysis; effector-target [E/T] ratio, 40:1) and the CD19(+) Raji cell line (mean, 78% +/- 17%) in contrast to nontransduced controls (8% +/- 8% and 3% +/- 2%).
|
20110422 |
2010 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunophenotypic profile at diagnosis was consistent with B precursor ALL (CD19, CD24, CD33 positive, weak CD13 positivity, CD10 negative) and both were negative for FLT3-D835/I836 and FLT3-ITD mutations.
|
21474181 |
2012 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The bone marrow was markedly hypercellular with a total infiltration of agranular lymphoid blast cells with a B-II (pre-B) lymphoblastic phenotype: cyCD79α(+), CD19(+), sCD22(+), CD10(+), CD20(-), CD34(+), and sIgM(-), with dim aberrant co-expression of the myeloid-associated markers CD13(+) and CD33(+).
|
23491079 |
2013 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We developed murine CD19-specific chimeric antigen receptors (CARs) and an immunocompetent mouse model of B-ALL that recapitulates the disease at genetic, cellular, and pathologic levels.
|
23585892 |
2013 |
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, complete clinical responses have been observed in small numbers of patients with B-ALL treated with adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule present in essentially all cases of B-ALL.
|
24319203 |
2013 |